The Integrated Translational Research has been created within the last cycle ofthe DDRCC, in 2007, as a centralized service aimed to address the needs of an increasing number of translational investigators in the field of digestive diseases at the University of Chicago. It replaces and expands the Clinical Component of the Administrative core, which was limited to assistance for clinical study design and IRB protocols. The Director, Dr. Bana Jabri, together with the Co-PI, Dr. David Rubin, is responsible for ensuring proper scientific direction and efficient use of services. Three main services will be offered: 1) Assistance to design and perform human studies. This service comprises: a) establishment of an umbrella IRB protocol, and help to obtain specific IRBs; b) assistance to design human studies; c) Personal training to perform phenotypic and translational studies on cell purified from intestinal samples; d) Bank of antibodies directed against common human antigens; and e) help for biostatistical analysis in collaboration with the University of Chicago CTSA. 2) Clinical database. This service comprises: a) Obtaining patient consent for clinical data and blood/ tissue acquisition; b) Implementation of a systematic first visit and follow-up clinical questionnaire for patients with inflammatory bowel disease; and c) implementation and maintenance of a longitudinal clinical Velos database system. Velos eResearch is a highly-regarded clinical research information system chosen by 20 medical institutions with top 25 ratings in U.S. 3) Tissue banking. We are implementing a LIMS (Lab Infonnation Management System) using the caTissue Suite for sample tracking and management. Furthermore, through a collaboration with TRIDOM project ((Translational Research in the Department of Medicine), DDRCC members will have access to DNA, blood and serum samples. Importantly, for DDRCC investigators with the appropriate IRB, it will be possible to match clinical database information with specific biospecimens. The IT core is a central piece ofthe DDRCC that is tightly linked to all other cores ofthe DDRCC. It provides DDRCC investigator with an infrastructure dedicated to integrated translational research in the field of inflammatory intestinal diseases. Patient databases will be integrated with collection of tissue/ DNA/RNA/protein specimens, genotyping, immunological phenotyping, and molecular profiling of patient bacterial microbiomes. This structure will also serve as an umbrella for the training and education of faculty and fellows in unique aspects of patient-oriented research.

Public Health Relevance

The goal of the integrated translational core is to provide an infrastructure that allows to link patient-oriented research and basic science. Establishing this link is critical to advance our understanding of intestinal inflammatory diseases and identify new therapeutic avenues.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK042086-25
Application #
8780628
Study Section
Special Emphasis Panel (ZDK1-GRB-8)
Project Start
Project End
Budget Start
2014-12-01
Budget End
2015-11-30
Support Year
25
Fiscal Year
2015
Total Cost
$177,219
Indirect Cost
$63,617
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Meisel, Marlies; Hinterleitner, Reinhard; Pacis, Alain et al. (2018) Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557:580-584
Chen, Edmund B; Cason, Cori; Gilbert, Jack A et al. (2018) Current State of Knowledge on Implications of Gut Microbiome for Surgical Conditions. J Gastrointest Surg 22:1112-1123
Chew, Justin; Leypunskiy, Eugene; Lin, Jenny et al. (2018) High protein copy number is required to suppress stochasticity in the cyanobacterial circadian clock. Nat Commun 9:3004
Ruderman, Sarah; Eshein, Adam; Valuckaite, Vesta et al. (2018) Early increase in blood supply (EIBS) is associated with tumor risk in the Azoxymethane model of colon cancer. BMC Cancer 18:814
Dugas, Lara R; Lie, Louise; Plange-Rhule, Jacob et al. (2018) Gut microbiota, short chain fatty acids, and obesity across the epidemiologic transition: the METS-Microbiome study protocol. BMC Public Health 18:978
McIntosh, Christine M; Chen, Luqiu; Shaiber, Alon et al. (2018) Gut microbes contribute to variation in solid organ transplant outcomes in mice. Microbiome 6:96
Overstreet, A M; LaTorre, D L; Abernathy-Close, L et al. (2018) The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis. Mucosal Immunol 11:1454-1465
Panés, Julian; Vermeire, Séverine; Lindsay, James O et al. (2018) Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis 12:145-156
Feagan, Brian G; Schwartz, David; Danese, Silvio et al. (2018) Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. J Crohns Colitis 12:621-626
Delmont, Tom O; Eren, A Murat (2018) Linking pangenomes and metagenomes: the Prochlorococcus metapangenome. PeerJ 6:e4320

Showing the most recent 10 out of 697 publications